Medpace Holdings, Inc. (NASDAQ:MEDP) Stock Position Raised by Nisa Investment Advisors LLC

Nisa Investment Advisors LLC increased its stake in Medpace Holdings, Inc. (NASDAQ:MEDP) by 6.9% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 701 shares of the company’s stock after acquiring an additional 45 shares during the quarter. Nisa Investment Advisors LLC’s holdings in Medpace were worth $233,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently modified their holdings of the stock. Iron Triangle Partners LP acquired a new position in shares of Medpace in the third quarter worth about $64,371,000. Clearbridge Investments LLC boosted its stake in Medpace by 55.1% in the 2nd quarter. Clearbridge Investments LLC now owns 403,892 shares of the company’s stock worth $166,343,000 after purchasing an additional 143,481 shares during the period. Wellington Management Group LLP grew its position in Medpace by 36.0% during the 3rd quarter. Wellington Management Group LLP now owns 415,255 shares of the company’s stock worth $138,612,000 after purchasing an additional 109,886 shares in the last quarter. DF Dent & Co. Inc. raised its stake in Medpace by 189.9% during the 3rd quarter. DF Dent & Co. Inc. now owns 161,298 shares of the company’s stock valued at $53,841,000 after purchasing an additional 105,659 shares during the period. Finally, Argent Capital Management LLC raised its stake in Medpace by 431.5% during the 3rd quarter. Argent Capital Management LLC now owns 91,732 shares of the company’s stock valued at $30,620,000 after purchasing an additional 74,473 shares during the period. 77.98% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research analysts have recently weighed in on MEDP shares. Robert W. Baird lifted their price target on Medpace from $354.00 to $362.00 and gave the company a “neutral” rating in a report on Monday. TD Cowen lowered their target price on Medpace from $413.00 to $372.00 and set a “buy” rating on the stock in a research note on Wednesday, October 23rd. Baird R W downgraded Medpace from a “strong-buy” rating to a “hold” rating in a report on Wednesday, October 23rd. William Blair restated an “outperform” rating on shares of Medpace in a report on Tuesday, October 22nd. Finally, Truist Financial dropped their price objective on shares of Medpace from $415.00 to $397.00 and set a “hold” rating on the stock in a research note on Monday, October 14th. Seven analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $381.44.

Medpace Trading Down 0.8 %

Medpace stock opened at $343.02 on Thursday. Medpace Holdings, Inc. has a 1-year low of $286.76 and a 1-year high of $459.77. The firm’s fifty day simple moving average is $341.77 and its 200-day simple moving average is $353.45. The company has a market capitalization of $10.66 billion, a P/E ratio of 30.04, a P/E/G ratio of 1.77 and a beta of 1.36.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.